Treatment with an antagonist reduced the expression of inflammasome components (including NLRP3, AIM2, and antimicrobial peptides) in the dermis, which indicated that targeting TLR-7, TLR-8, and TLR-9 may provide a method for neutralizing the multiple inflammatory pathways that are involved in psoriasis. This evidence concerns the gene TLR7 and psoriasis.